New PML case hits Tysabri
This article was originally published in Scrip
Executive Summary
Another case of PML (progressive multifocal leucoencephalopathy) in a multiple sclerosis patient receiving ElanandBiogen Idec's Tysabri (natalizumab) has sent shares in both firms tumbling.